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To investigate the role of type I interferon (IFN) and its regulatory transacting proteins, interferon regulatory factors (IRF-1
and IRF-2), in early protection against infection with virulent Venezuelan equine encephalitis virus (VEE), we utilized mice with
targeted mutations in the IFN-a/b receptor, IRF-1, or IRF-2 genes. IFN-a/b-receptor knockout mice are highly susceptible to
peripheral infection with virulent or attenuated VEE, resulting in their death within 24 and 48 h, respectively. Treatment of
normal macrophages with anti-IFN-a/b antibody prior to and during infection with molecularly cloned virulent VEE resulted
in increased VEE replication. However, treatment with high doses of IFN or IFN-inducing agents failed to alter percentage
mortality or average survival times in mice challenged with a low dose of virulent VEE. In IRF-1 and IRF-2 knockout mice
(IRF-12/2 and IRF-22/2), the 100% protection against virulent VEE that is conferred by attenuated VEE within 24 h in control
C57BL/6 mice was completely absent in IRF-22/2 mice, whereas 50% of IRF-12/2 mice were protected. IRF-22/2 mice were
deficient in clearing VEE virus from the spleen and the brain compared to the heterozygous IRF-21/2 knockout or C57BL/6
(1/1) mice. Furthermore, a distinct pattern of histopathological changes was observed in brains of IRF-22/2 mice after VEE
exposure. Taken together, these findings imply that the altered immune response in IRF-1 and IRF-2 knockout mice results
in altered virus dissemination, altered virus clearance, and altered virus-induced pathology. Thus, type I interferon, as well
as IRF-1 and IRF-2, appears to play an important and necessary role in the pathogenesis of, and protection against, VEE
infection.
n
t
c
i
i
b
r
e
e
i
p
l
i
S
a
i
c
u
M
r
i
a
m
rThe genus alphavirus, with its over 26 recognized
embers, is widely distributed throughout the Old and
ew Worlds (Watts et al., 1997). Venezuelan equine en-
ephalitis virus (VEE) is one of the human alphavirus
athogens that is found exclusively in the Americas,
ausing epidemic outbreaks in South and Central Amer-
ca, with occasional outbreaks in southern North Amer-
ca (Bowen, 1976).
In contrast to some members of the alphavirus genus
hat cause persistent infections, VEE induces an acute,
ebrile disease with potential progression to the central
ervous system (CNS) and the development of encephali-
is. In the murine model, it has been shown that the initial
mmune response to this acute CNS infection is critical in
he protection against lethal encephalitis (Grieder et al.,
997). These early responses against viral infections have
een postulated to include innate immune mechanisms,
uch as activation of macrophages, because macrophages
nd other myeloid cells, such as dendritic cells, perform
ssential roles during the early immune response against
irus infections of the CNS (Balter, 1996). The role of mac-
ophages in viral CNS infections is very complex, mainly
ecause their function appears to be highly virus-specific.
or example, following Theiler’s virus infection in mice, the
1 To whom correspondence and reprint requests should be ad-
cressed. Fax: (301) 295-1545. E-mail: fgrieder@mxb.usuhs.mil.
042-6822/99 106umber of macrophages increases significantly, and deple-
ion of macrophages prior to infection results in a de-
reased inflammatory response and absence of persistent
nfection (Rossi et al., 1997). In contrast, West Nile virus
nfection in macrophage-depleted mice resulted in exacer-
ated disease (Ben-Nathan et al., 1995). Furthermore, mac-
ophages can provide virus access to the brain (Chebloune
t al., 1998), contribute to host cell death, and help the virus
vade detection by the immune system (Balter, 1996).
The interaction between macrophages and VEE during
nfection is not clearly understood. In early comparative
athology studies, VEE’s tropism for neuronal, myeloid, and
ymphoid tissues was described in rodents, with patholog-
cal lesions in CNS and non-CNS sites (Victor et al., 1956).
ignificant myeloid cell death in the spleen, lymph nodes,
nd bone marrow was described (Victor et al., 1956). The
nvolvement of myeloid cells in VEE pathogenesis was later
onfirmed in studies in which VEE pathogenesis was eval-
ated (Grieder and Nguyen, 1996; Jackson et al., 1991).
oreover, in recent studies using replication-deficient VEE
eplicons, dendritic cells were identified as the first targets
n mice after peripheral infection with VEE (MacDonald et
l., 1997). Finally, the activation or differentiation state of
acrophages has been shown to be important in VEE
eplication (Grieder and Nguyen, 1996).
Protection against VEE infection has generally beenorrelated with the induction of a neutralizing antibody
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107IFN AND IRFs IN EARLY PROTECTION AGAINST VEEiter (Pittman et al., 1996; Rivas et al., 1997). In mice,
eutralizing anti-VEE antibodies were observed in the
erum, as was a mucosal response (Charles et al., 1997;
reenway et al., 1995), following subcutaneous infection,
lthough protection was mouse strain-specific (Hart et
l., 1997). Protection against lethal VEE challenge of mice
as also observed when mice were treated with immune
pleen cell culture supernatants that contained interleu-
in-1 and -2 (Huprikar et al., 1990) or when “vaccinated”
ith molecularly cloned, attenuated VEE 24 h prior to
hallenge with virulent VEE (Grieder et al., 1997). The
echanism of this nonspecific protection against VEE is
ot well understood at present, but macrophages and
ther soluble immune mediators may play an important
ole. Mice with a severe combined immunodeficiency,
nfected with virulent VEE, survived longer than did intact
ice infected with the same virus (Dr. Peter Charles,
ersonal communication). These results further support
he hypothesis that the initial, nonspecific response to
he infection is important because it allows the immune
esponse time to develop and confer solid protection.
Key immune mediators in virus elimination include the
nterferons (IFN). In previous studies conducted with
indbis (SB) virus infection in mice, an important corre-
ation between SB virulence and the level of IFN-a/b
nduction was established (Trgovcich et al., 1996). The
orking hypothesis was that rapid spread of virulent SB
irus led to high IFN-a/b levels and, possibly, those of
ther cytokines. Rapidly replicating, virulent SB virus
vades the innate immune response by accelerated in-
uction of specific proinflammatory cytokines and a sys-
emic stress response (Trgovcich et al., 1997). In con-
rast, a single-site-attenuated SB virus, which exhibits a
educed replication capacity, induced IFN-a/b levels with
ifferent kinetics, resulting in extended survival and al-
ered pathology. Further, Semliki Forest virus (SFV) infec-
ion in neonatal, type I interferon receptor knockout
IFNAR1) mice resulted in rapid death and high virus
iters in organs (Hwang et al., 1995; Muller et al., 1994).
IFN-a/b induction and the establishment of an antiviral
tate is regulated by IFN-inducible genes or transcriptional
egulators and their mechanism of activation. Two structur-
lly related molecules, interferon regulatory factor-1 and -2
IRF-1 and IRF-2), are transcriptional regulators of IFN that
ct to activate and suppress gene expression, respectively,
y binding to DNA regulatory elements in the IFN-a/b
romoter and in the promoters of many IFN-inducible
enes (Pitha, 1997; Nguyen et al., 1997). Both IRF-1 and
RF-2 have been implicated in the induction of IFNs (Kimura
t al., 1994) and of nitric oxide by macrophages (Kamijo et
l., 1994) following virus infection in mice. Additionally, IRF-1
nd IRF-2 were shown to be induced by other proinflam-
atory cytokines (Fujita et al., 1989; Harada et al., 1989;
ehtonen et al., 1997).
In the studies reported here, we utilized mice with tar-eted mutations in the IFN-a/b receptor (IFNAR1), as well es mice with targeted mutations in the IRF-1 and IRF-2
enes. All three mouse strains exhibit increased suscepti-
ility to infection with virulent VEE, and both IFNAR1 and
RF-2 knockout mice exhibit increased susceptibility to the
ttenuated VEE strain. Further, we show that treatment of
ormal macrophages with anti-IFN-a/b antibody resulted in
ncreased replication of cloned virulent V3000. Administer-
ng exogenous IFN and IFN inducers failed to protect mice
rom VEE. Taken collectively, these findings imply that the
efective immune response in the three knockout strains
esults in both increased initial virus dissemination and
ltered virus clearance. Thus, type I interferon appears to
lay an important and necessary, though not sufficient, role
n the pathogenesis of, and protection against, VEE infec-
ion.
RESULTS
To evaluate the role of IFN-a/b in VEE infection, the
usceptibility of IFN-a/b-receptor knockout mice to VEE
as tested. Groups of five mice were infected in their left
ear footpad with either attenuated V3032 alone or the
ombination of attenuated V3032 followed by virulent V3000
4 h later. Control 129Sv/Ev mice, the parental strain of the
FNAR1 mice, were injected likewise. Attenuated V3032 or
ombination attenuated/virulent VEE infection in the
29Sv/Ev mice resulted in mortalities and average survival
imes similar to those observed in C57BL/6 or CD-1 mice:
he mutated strain, V3032, was completely avirulent at 1 3
03 PFU and induced protection against lethal challenge
ith virulent V3000 in 80% of the mice (Table 1).
In contrast, there was 100% mortality in IFNAR1 mice
nfected with either the attenuated strain only or the dual
hallenge regime. Moreover, these mice exhibited ex-
remely short average survival times of less than 1 day
Table 1). This is significantly shorter than the average
urvival time in control C57BL/6 mice infected with viru-
ent V3000, which typically die after 7 to 9 days (Grieder
TABLE 1
IFN-a/b Receptor Knockout (IFNAR1) Mice Are Highly Susceptible
to Attenuated and Virulent VEE Infection
Mouse strain
VEE
challenge
AST 6 SE
(days)
Mortality
%
29Sv/Ev (1/1) V3032 — 0
V3032/V3000 8.0 20
FNAR1 (IFN-a/b R2/2) V3032 1.0 6 0 100
V3032/V3000 0.4 6 0.5 100
Note. Groups of five adult IFNAR1 mice were infected in their rear
ootpads with either 103 PFU attenuated V3032 alone or the combina-
ion of 103 PFU attenuated V3032 followed by 102 PFU virulent V3000
4 h later. 129Sv/Ev mice, the parental strain of the IFNAR1 mice,
erved as controls. The average survival times (AST) were calculated in
ays 6 standard error (SE) after V3000 inoculation.t al., 1997). Therefore, IFN-a/b appears to play a critical
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108 GRIEDER AND VOGELole in very early VEE pathogenesis and, specifically, in
reventing disease by attenuated V3032.
nti-IFN-a/b antibody affects the growth of virulent,
ut not avirulent, VEE in peritoneal macrophages
Treatment of primary peritoneal macrophage cultures
ith IFN-a/b antibody resulted in increased levels of
irulent V3000 replication (Fig. 1a). At 24 h postinfection,
here was a .10-fold increase in VEE titer in the culture
upernatants of antibody-treated cells compared to con-
rol antibody-treated cells. Peak virulent V3000 titers
eached almost 1 3 108 PFU/ml at 24 h, 24 h before peak
iters were reached in control-treated cells. Over the
ourse of the next several days, the virulent V3000 titer in
he anti-IFN-a/b antibody-treated cultures remained ele-
ated (;8-fold) compared to the titers in control cultures.
n contrast, treatment of primary macrophage cultures
ith identical concentrations of neutralizing IFN-a/b an-
ibody failed to result in increased attenuated V3032
iters compared to titers in control cultures (Fig. 1b).
rowth kinetics of the attenuated VEE in either treated or
ntreated macrophage cultures were comparable over
he entire observation period.
FN-b and IFN inducers fail to protect mice against
ow-level virulent V3000 infection
Groups of 8-week-old C57BL/6 mice were treated in-
raperitoneally with IFN-b, Poly I:C, or LPS 24 h prior to
hallenge with 1 3 102 PFU of virulent V3000 into the left
ear footpad. Serum IFN levels of mice treated with IFN,
oly I:C, LPS, or PBS were measured by standard bio-
ogical assay on L929 cells (Trgovcich et al., 1996) in
ontrol mice 24 h posttreatment and were 1600, 6400,
00, and 20 U/ml, respectively. Mice pretreated with
FN-b, Poly I:C, or LPS all died, with average survival
imes similar to those of mice pretreated with diluent
Table 2). Further, mice infected in the right rear footpad
ith 1 3 103 PFU of attenuated V3032 24 h prior to
hallenge with the same dose of virulent VEE survived
he challenge without any symptoms of disease (data not
hown). These results indicate that elevated serum IFN
iters alone are not sufficient to confer protection against
ow-dose, peripheral virulent VEE challenge.
irulent VEE mortality in mice with targeted mutations
n their IRF-1 or IRF-2 genes
Mice between 8 and 20 weeks of age were tested in
hree independent experiments (compiled in Figs. 2a–2f).
roups of mice ranged from 8 to 27 animals, with both
exes equally represented. Molecularly cloned virulent
3000 caused 100% mortality in control C57BL/6, homo-
nd heterozygous knockout mice for the IRF-2 gene
IRF-22/2 or IRF-21/2), and homozygous IRF-12/2 mice
Fig. 2). Surprisingly, two IRF-11/2 mice injected with
ither 10 or 102 PFU of virulent V3000 survived. These rwo mice were subsequently protected against intraperi-
oneal challenge with 1 3 104 PFU virulent VEE 1 week
ater. Survival of the second V3000 challenge confirmed
hat the two surviving mice had been exposed to VEE
nd developed a protective immune response. There-
ore, the mortality rate was 96% for IRF-11/2 mice. Thus,
he overall mortality rate of virulent V3000 for adult mice
n these experiments was 99.2%. AST following rear
ootpad infection of V3000 ranged from 6.1 to 9.7 days p.i.
ome trends in the survival data were observed in terms
f infectious dose, age, and sex, but none were signifi-
antly different by statistical analysis. Specifically, higher
oses decreased average survival time and younger
dult mice died from V3000 infection earlier than did
lder mice, while male mice perished from VEE infection
omewhat faster compared to age-matched females.
Interestingly, while the homozygous (2/2) IRF-1 and
RF-2 knockout mice died sooner compared to either the
57BL/6 or the heterozygous (1/2) controls, a trend that
learly increased with increased virus dose, at the lowest
3000 dose of 10 PFU, both IRF-11/2 and IRF-21/2 heterozy-
ous mouse strains appeared to survive longer than either
he homozygous knockout or the C57BL/6 control strains.
ince neither the IRF-1 nor the IRF-2 mice are completely
nbred onto the C57BL/6 background, this suggests that
enes other than IRF-1 and IRF-2 that are present on the
eterozygotic background or C57BL/6 mouse may contrib-
te to resistance or susceptibility, respectively.
ailure of attenuated V3032 to protect IRF-1 or IRF-2
nockout mice challenged with virulent V3000
As seen in Fig. 2, V3000 kills virtually all mice; homozy-
ous IRF-1 and IRF-2 knockouts die more rapidly than do
57BL/6 or heterozygous IRF-11/2 or IRF-21/2 control mice.
ear footpad inoculation of 1 3 103 PFU of attenuated
3032 24 h prior to challenge with a lethal dose of virulent
3000 (1 3 102 PFU into the opposite rear footpad) resulted
n 100% survival of adult C57BL/6 mice, as has been pre-
iously demonstrated (Grieder et al., 1997) (Fig. 3). Groups
f age- and sex-matched homozygous and heterozygous
RF-1 or IRF-2 knockout mice were inoculated either with
he same two virus inoculation regimes (attenuated V3032
ollowed 24 h later by virulent V3000) or with virulent V3000
nly (1 3 102 PFU) into the rear footpad(s). In contrast to the
ontrol C57BL/6 mice,homozygous knockout mice exhib-
ted either 44%(IRF-12/2) or no (IRF-22/2) protection when
njected with both viruses. IRF-1 and IRF-2 heterozygous
ice exhibited intermediate phenotypes with 89 and 50%
rotection, respectively. These results indicate that deletion
f IRF-2 eliminates a critical factor (or factors) that is in-
olved in the early protection against lethal peripheral VEE
nfection induced within 24 h by inoculation with the atten-
ated V3032 strain. IRF-1 also appears to play an importantole in this induction of early protection, because heterozy-
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109IFN AND IRFs IN EARLY PROTECTION AGAINST VEEFIG. 1. Growth kinetics of virulent and attenuated VEE in peritoneal macrophages treated with anti-IFN-a/b antibody. Thioglycollate-elicited
eritoneal macrophages from C57BL/6 mice were treated with sheep anti-IFN-a/b antibody prior to and following infection with virulent or attenuated,
olecularly cloned VEE, V3000 or V3032, respectively. Cell culture medium was supplemented with a 1:10 dilution anti-IFN-a/b antibody (neutralizing
iter of 106 against 8 U of IFN-a/b) and cultures were infected at a multiplicity of infection of 1.0. Culture supernatants were harvested and standard
laque assays performed on BHK-21 cells.
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110 GRIEDER AND VOGELous IRF-11/2 mice are highly protected, while deletion of
oth IRF-1 alleles results in only 50% survival.
Control groups infected with the challenge dose of 1 3
02 PFU of virulent V3000 died in a pattern similar to that
bserved in the combined large group of mortality (com-
are to Figs. 2c and 2d). Because of the 100% mortality
bserved in dually injected IRF-22/2 mice, a further group
f 5 IRF-22/2 mice was injected with 2 3 103 PFU of
ttenuated V3032. In contrast to control mice, only 60% of
he IRF-22/2 mice survived this infection with an average
urvival time of 10.5 6 0.7 days (data not shown). All 10
eterozygotic IRF-21/2 and C57BL/6 control mice injected
ith the same attenuated V3032 virus survived without
ny clinical signs of disease.
irulent and attenuated VEE growth kinetics in
rimary peritoneal macrophages from homozygous
RF-22/2 and heterozygous IRF-21/2 mice
During the initial 24 h p.i., virulent V3000 titers in IRF-2
nockout macrophages appeared similar to those in mac-
ophages from control C57BL/6 mice. The typical exponen-
ial virus growth during the first 12 to 24 h of infection
ulminated in peak virus titers around 24 h p.i. Levels of
eak titers depend on the original virus inoculum and the
umber of infected cells per culture dish, but usually persist
or approximately 24 h in control C57BL/6 macrophages
Grieder and Nguyen, 1996). Thereafter, in both homozy-
ous and heterozygous IRF-2 knockout macrophages, peak
iters dropped significantly, resulting in 25- to 50-fold lower
EE titers at 48 and 72 h p.i. (Fig. 4a).
Similarly, attenuated V3032 growth kinetics in macro-
hages elicited from IRF-22/2 knockout mice was com-
arable to V3032 growth kinetics in IRF-21/2 macro-
hages (Fig. 4b). Identical attenuated and virulent VEE
rowth kinetics studies were also established in macro-
hages derived from IRF-12/2 and IRF-11/2 mice (data not
TABLE 2
Percentage Mortality and Average Survival Times in Mice Treated
ith Interferon or Interferon-Inducing Agents Prior to Infection with
irulent VEE
Treatment
AST 6 SE
(days)
Mortality
%
PBS 8.4 6 0.9 100
IFN-b 8.4 6 0.9 100
Poly I:C 9.0 6 0.7 100
LPS 7.0 6 0.7 100
Note. Groups of six adult, female C57BL/6 mice were intraperitone-
lly injected with 80,000 Units of interferon-b (IFN-b), 0.2 mg of poly(rI):
oly(rC) (Poly I:C), 25 mg lipopolysaccharide (LPS), or phosphate-buff-
red saline (PBS) 24 h before rear footpad challenge with 102 PFU of
3000. Percentage mortality was calculated for an observation period
f 14 days and the average survival times (AST 6 SE) were determined.hown). No significant differences in growth kinetics vere observed between macrophages from the homozy-
ous and the heterozygous knockout mice or in those
rom control mice. These results indicate the VEE growth
inetics in macrophages, as determined by in vitro
rowth pattern, do not appear to play a major role in the
mportant differences of early VEE protection conferred
y attenuated V3032 infection.
EE titers in IRF-22/2 mice following VEE infection
Independent of genetic background, in all mice in-
culated with virulent V3000 only, virus was recovered
rom the brain on days 7 and 8 p.i. This observation is
onsistent with the 100% mortality rate of virulent
3000 infection in mice. Titers were consistently high
t 1 3 106 to 1 3 107 PFU/gram brain tissue (data not
hown). In contrast, none of the mice inoculated with
ttenuated V3032 alone had a measurable VEE titer
data not shown). For the control C57BL/61/1 mice, this
bservation is consistent with previous reports char-
cterizing attenuated V3032 dissemination; specifi-
ally, V3032 fails to invade the CNS (Grieder et al.,
995). However, it was somewhat surprising that no
3032 was recovered from the brains of V3032-
nfected IRF-22/2 mice, because in these knockout
ice, V3032 caused 40% mortality.
VEE invasion of and clearance from the brain following
ual VEE infection differed drastically between the C57BL/
1/1 and the IRF-22/2 mouse strains (Table 3). In IRF-22/2
ice, which are not protected when peripherally primed
ith attenuated V3032 prior to challenge with 1 3 102 PFU
f virulent V3000, 30, 60, and 80% of mice had VEE titers
bove the level of detection in their sera, spleen tissue, and
rain tissue, respectively. The relatively low percentage of
erum-positive mice implied that the observed VEE-positive
issues were not exclusively a result of contaminating se-
um (e.g., several mice with serum titers below 30 PFU/ml
ad positive spleen or brain titers). In contrast, 50% of the
57BL/61/1 mice tested positive in the brains, while all
57BL/61/1 serum and spleen titers were below the level of
etection (i.e., 150 PFU/g fresh tissue). It was somewhat
urprising that in the C57BL/61/1 mice, which usually sur-
ive virulent V3000 challenge when treated 24 h earlier with
he attenuated V3032, 50% of the mice tested positive for
EE in their brains. Further, the average titer in the brains of
he surviving C57BL/61/1 mice was significantly lower on
ays 7/8 p.i. compared to that measured in IRF-22/2 mice,
.g., 6 3 105 PFU versus 5 3 107 PFU per gram. These
indings indicate that IRF-2 knockout mice were less effi-
ient than the control mice in clearing VEE.
istopathological changes in brain sections from
RF-22/2 mice following VEE infection
Coronal sections from mock-infected adult mice of
ither the C57BL/6 or the IRF-22/2 background showed
ery little histological difference when anatomically
i
s
c
111IFN AND IRFs IN EARLY PROTECTION AGAINST VEEFIG. 2. Virulent VEE mortality in mice with mutated genes for interferon regulatory factors 1 and 2 (IRF-12/2 and IRF-22/2). Groups of mice were
njected into their left rear footpad with molecularly cloned virulent V3000 at a dose of 10 (a and b), 100 (c and d), or 1000 (e and f) PFU. Percentage
urvival was calculated for an observation period of 15 days. Survival of IRF-12/2 and IRF-22/2 was compared to age-matched groups of C57BL/6
ontrol mice (data not shown) and heterozygous IRF-11/2 and IRF-21/2 littermate controls.
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112 GRIEDER AND VOGELdentical sections were compared (Figs. 5A and 5B).
inor differences were observed in the cerebellum
reduced ratio of the molecular to the granular layer in
RF-22/2 mice), while the appearance of the cerebrum
n both the gray and the white matter was without
ignificant differences.
On day 5 post-dual infection with attenuated and
irulent VEE, mild to moderate signs of encephalitis
ere observed in the brain of one C57BL/6 mouse.
his was the only one of four mice that had a signifi-
ant VEE brain titer at that time (1 3 106 PFU/g tissue;
ata not shown). Coronal sections throughout the en-
ire brain were characterized by mild neuronal degen-
ration with hyperchromatic cells, perivascular cuffing
ith lymphocyte infiltrate, and gliosis with activation of
icroglia and astrocytes (Fig. 5C). These histopatho-
ogical changes were comparable to those in brains
rom mice infected with virulent V3000 alone (data not
hown). In contrast, anatomically similar brain sec-
ions from age-matched IRF-22/2 mice infected with
he same dual VEE infection were characterized by a
oderate to severe degree of neuronal degeneration
ith much more significant vacuolization (Fig. 5D).
lso, activation of glial cells was much more pro-
FIG. 3. Attenuated VEE-induced protection against virulent VEE challe
nd IRF-22/2). Nine or ten adult C57BL/6 or homozygous or heterozygou
3032 into the left rear footpad 24 h before challenge with 1 3 102 PFU o
or an observation period of 14 days. All surviving mice were challeng
urvived without any clinical signs of encephalitis.ounced, resulting in moderate gliosis. However, there eas a complete absence of perivascular cuffing with
nfiltrating lymphocytes. In 10 coronal brain sections
btained from infected IRF-22/2 mice, not a single
lood vessel with infiltrating lymphocytes was ob-
erved, while 5 of 10 analyzed coronal brain sections
rom infected C57BL/6 mice had up to 32 blood ves-
els with the characteristic perivascular cuffing and
ellular infiltrate. Moreover, microscopic analysis of
he number of degenerative neurons in C57BL/6 in-
ected brain sections resulted in a mean value of 5.6 6
.6 cells per high-power field. This is in contrast to a
ean of 23.4 6 5.8 degenerative neurons in similar
rain sections from IRF-22/2 mice infected with the
ame two VEE strains (P , 0.001).
On day 8 post-dual infection, no significant his-
opathological changes were observed in any of four
57BL/6 mice analyzed. However, coronal sections
rom all five IRF-22/2 mice infected with the identical
wo viruses and sacrificed at 8 days postinfection
resented with similar neuronal degeneration and
acuolization in the brain as described on day 5
ostinfection. Further, there was no significant inflam-
atory response observed in any of the IRF-22/2 brain
ections. These observations, together with the appar-
mice with deleted interferon regulatory factors-1 and -2 genes (IRF-12/2
or IRF-2 knockout mice were injected with 1 3 103 PFU of attenuated
nt V3000 into the right rear footpad. Percentage survival was calculated
aperitoneally with 1 3 104 PFU of virulent V3000 at 3 weeks p.i. andnge in
s IRF-1
f virule
ed intrnt failure of IRF-22/2 mice to clear the virus (see Table
3
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113IFN AND IRFs IN EARLY PROTECTION AGAINST VEE) or to develop protection (see Fig. 3), indicate impor-
ant differences in the IRF-22/2 mice’s neuropathogen-
FIG. 4. Virulent and attenuated VEE growth kinetics in primary perito
heir interferon regulatory factor-2 gene (IRF-22/2 and IRF-21/2). Thiogly
RF-21/2 mice were infected at a multiplicity of 1.0 with molecularly clo
ndependent tissue culture wells were harvested and virus titers were d
ndicate peritoneal macrophages from thioglycollate-treated IRF-22/2 osis of VEE infection. No significant histopathological shanges were observed in brain sections from mice
nfected with the attenuated V3032 alone (data not
crophages from mice with homozygous or heterozygous mutations in
-elicited peritoneal macrophages from control C57BL/6 or IRF-22/2 or
tenuated V3032 or virulent V3000. Cell culture supernatants from two
ned by standard plaque assay using BHK-21 cells. IRF-22/2 or IRF-21/2
1/2 mice, respectively.neal ma
collate
ned at
etermihown).
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114 GRIEDER AND VOGELDISCUSSION
he role of type I IFN in early VEE protection
VEE contains a single-stranded, positive-sense RNA
enome in an icosahedral nucleocapsid that is enclosed
n a host cell membrane-derived envelope (reviewed by
trauss and Strauss, 1994). Two virus-encoded glyco-
roteins, E1 and E2, are inserted into this envelope and
resent in icosahedral organization as spikes on the
urface. Among other functions, the VEE spikes have
een shown to play important roles in virus interaction
ith the host’s immune cells (Bose and Sagik, 1970;
avis et al., 1986, 1995). In all experiments discussed in
his communication, we used the two molecularly cloned
EE, which differed by only one amino acid in the glyco-
rotein spike (Davis et al., 1991; Grieder et al., 1995).
In this report, we showed that type I IFN is necessary
n the initial response to VEE infection, as demonstrated
y the accelerated, lethal course of attenuated VEE in-
ection in IFNAR1 mice. Our observation is further sup-
orted by the findings that (i) in vivo anti-IFN-a/b anti-
ody treatment of mice decreased average survival time
f virulent V3000-infected animals (Grieder et al., 1997)
nd (ii) in vitro anti-IFN-a/b antibody treatment of primary
eritoneal macrophage cultures prior to virulent VEE
nfection results in higher VEE titers than in control cul-
ures. These findings parallel those in a different model,
.g., SFV infection in neonatal mice, in which IFNAR1
ice died rapidly following SFV infection (Muller et al.,
994; Hwang et al., 1995).
However, in both the VEE and the SFV systems, IFN was
ot sufficient to protect against virus challenge. In this study
e demonstrated that intraperitoneal administration of ei-
her 80,000 U of recombinant IFN-b or the IFN-inducing
gent, Poly I:C, resulted in serum IFN levels 24 h after
njection of 1600 and 6400 U/ml, respectively, yet failed to
rotect mice challenged with 100 PFU of virulent VEE. The
verage survival times of these mice were identical to
hose of mice treated with PBS prior to infection with viru-
ent V3000. These findings are consistent with those in
nother study using the IFN-inducer Poly I:C to treat SFV
T
VEE Titers in Serum and Spleen and Brain Tissues from Mice Fo
Mouse strain
(number of animals)
V
Serum
% pos Titer
C57BL/6 (6) 0 ,30
IRF-22/2 (10) 30 3 3 104
Note. Groups of adult C57BL/6 and IRF-22/2 mice were infected into t
ith 102 PFU of V3000 into their right rear footpad. Detection levels fonfection in mice (Coppenhaver et al., 1995), in that Poly I:Clone failed to reduce mortality following SFV infection. In
hat study, the estimated measured IFN levels reached 1 3
04 U/ml serum, similar to those measured in sera of neo-
atal mice infected with attenuated SB virus (Trgovcich et
l., 1996), while infection of neonatal mice with virulent SB
irus resulted in serum IFN levels of 105 U/ml (Trgovcich et
l., 1996). The higher IFN titers in the SB virus study were
ssociated with reduced average survival times of the host.
hese results may be explained by different IFN sensitivity,
ifferent IFN-induction kinetics, or additive effects of differ-
nt immunomodulators. We conclude from ours and these
tudies that IFN alone is insufficient to elicit a protective
esponse to VEE.
he role of interferon regulatory factor in VEE
nfection
To understand the role of IFNs in VEE pathogenesis
nd protection, the potential role of IFN gene transcrip-
ional regulators deserves evaluation. This group of tran-
cription regulatory factors, called IRFs (Fujita et al.,
988; Miyamoto et al., 1988), functions as activator, re-
ressor, and activation/repressor combinations for IFN
ene transcription (Pitha, 1997). Harada and colleagues
emonstrated that some are constitutively expressed (IRF-1
nd -2) (Harada et al., 1989), while others (IRF-1) are in-
uced following exposure to virus, to type I IFN, or to other
ytokines (Fujita et al., 1989; Miyamoto et al., 1988). How-
ver, the role of IRFs in virus infections appears to be highly
irus-specific. In initial reports, it was hypothesized the
RF-12/2 mice should display decreased or absent IFN
evels and therefore should evidence increased virus rep-
ication. Alternatively, IRF-22/2 mice were predicted to have
ormal or increased IFN levels, which could result in re-
uced virus replication and extended survival times. Infec-
ion of IRF-12/2 mice with encephalomyocarditis virus did
ndeed result in increased virus titers in the brain and heart
f infected mice and in reduced average survival times,
hile infection with vesicular stomatitis virus or herpesvirus
esulted in little or no change in the pathogenicity of such
nfected mice (Kimura et al., 1994).
Peripheral Infection with Attenuated V3032 and Virulent V3000
rs on days 7 or 8 postinfection
Spleen Brain
pos Titer % pos Titer
0 ,150 50 6 3 105
60 4 3 102 80 5 3 107
t rear footpad with 103 PFU of attenuated V3032 followed by challenge
were 30 PFU/ml; for tissue, 150 PFU/g.ABLE 3
llowing
EE tite
%
heir lefIn our experiments, we found that both IRF-1 and IRF-2
k
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m
m
e
d
C
D
115IFN AND IRFs IN EARLY PROTECTION AGAINST VEEnockout mice are highly susceptible to infection with mo-
ecularly cloned virulent and single-site-attenuated VEE.
lthough average survival times were not statistically dif-
FIG. 5. Histopathology analysis of coronal brain sections in IRF-22/2
escribed in Table 3 and brain sections were subjected to staining wit
57BL/6, and B, IRF-22/2) are shown in comparison to mice injected w
, IRF-22/2) at 6 days postinjection. Original magnification 2003.erent between the homozygous and the heterozygous 1ice in both the IRF-1 and the IRF-2 mouse strains, ho-
ozygous knockout mice always died before their het-
rozygous litter mates, at all levels of virus challenge (10,
following VEE infection. Groups of mice were inoculated with VEE as
toxylin and eosin. Histological appearance of mice mock injected (A,
nuated V3032 followed by virulent V3000 24 h later (C, C57BL/6, andmice
h hema
ith atte00, and 1000 PFU of virulent V3000 per mouse).
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116 GRIEDER AND VOGELOne notable observation is that two IRF-11/2 mice
noculated with virulent V3000 at doses of 10 and 100
FU, respectively, survived the initial infection and were
rotected against subsequent challenge with a more
ighly concentrated VEE dose. These two mice came
rom a cohort of 216 homozygous and heterozygous IRF
nockout mice. This is significant, because in over 1000
57BL/6 mice injected with virulent V3000 over several
ears, survival was never observed after infection with
ny dose higher than 1 PFU. This leads to the interesting
peculation that disruption of one IRF-1 allele may affect
xpression of IRF-2, subsequently altering regulation of
FN and, perhaps, other factors. If confirmed, such im-
roved resistance to virulent infection suggests that a
otential new pathway might exist in early protection.
here is further tantalizing evidence of a gene dosage
ffect and the relative contribution of IRF-1/2 to this
ystem: heterozygous IRF-11/2 and IRF-21/2 mice always
urvived homozygous knockout mice; but IRF-11/2 mice
ere significantly more protected by attenuated V3032
han IRF-21/2 mice.
We generated supportive data for the hypothesis that
eletion of the IRF-2 locus increases the severity of VEE
nfection by demonstrating that IRF-22/2 mice clear virus
rom the brain and the spleen more slowly than IRF-21/2
ice (data not shown). This slow or absent viral clearance
as shown by an increasing virus brain titer in the IRF-22/2
ice by day 8 p.i. Similarly, slower clearance and increased
issue virus titers in IRF-22/2 mice were also found when
hey were compared to the C57BL/6 strain.
VEE infection in mice with genetically altered IRF-2
enes showed clear evidence of altered initial inflamma-
ory response and subsequent neuronal degeneration.
ive days postinfection with the combination of V3032
nd V3000 24 h apart, one of four C57BL/6 mice had a
irus brain titer of 1 3 106 PFU/g tissue. This mouse
howed typical histopathological changes associated
ith VEE-induced encephalitis, i.e., perivascular cuffing
ith lymphocyte infiltrate and mild neuronal degenera-
ion with glial activation. These histopathological
hanges contrasted with those observed in IRF-22/2
ice infected with the same virus stocks and doses. The
RF-22/2 mice showed a complete absence of perivascu-
ar cuffing or infiltrating lymphocytes and more moderate
o severe neuronal degeneration with significant vacuol-
zation. Additionally, there was significant glial cell acti-
ation resulting in pronounced gliosis. The absence of
nflammatory cells indicates that the responses to pe-
ipheral VEE infection are altered in IRF-22/2 mice.
In summary, we demonstrated that type I IFN is neces-
ary, but not sufficient, for early protection against virulent
EE infection. Further, we showed that early protection
gainst VEE is dependent on IRF-2 and to a lesser extent on
RF-1. And finally, we found the IRF-22/2 mice show a re-
uced inflammatory response to VEE infection that may beinked to the reduced capacity to clear virus from both the geriphery and the CNS. We speculate that this altered
ctivation of proinflammatory cells is related to proinflam-
atory products such as reactive nitrogen intermediates,
hich have been shown to be down-regulated in IRF-12/2
nd IRF-22/2 macrophages (Salkowski et al., 1996) and
RF-12/2 mice (Fujimura et al., 1997).
MATERIALS AND METHODS
nimals
Eight to 20-week-old IRF-1 and IRF-2 knockout mice (IRF-
2/2 and IRF-22/2) were obtained originally from Dr. Tak
ak (Amgen Institute, Toronto, Canada). IRF-12/2 and IRF-
2/2 mice were generated by targeted disruption in the
mbryonic stem cell using the neomycin resistance gene
neor) (Matsuyama et al., 1993). Mice were backcrossed to
57BL/6 mice before the establishment of IRF-12/2 and
RF-22/2 mouse colonies which were maintained at USUHS.
he genotype of all IRF-1 and IRF-2 mice was determined
y PCR using the primers and methods described previ-
usly (Salkowski et al., 1996). The IRF-1 and IRF-2 primers
mplify a 300- and 100-bp sequence, respectively, from
enomic DNA. For the backcross breeding, 10-week-old
57BL/6 mice were obtained from The Jackson Laboratory
Bar Harbor, ME), while for experimental controls, age-
atched C57BL/6 (1/1) mice were obtained from the Na-
ional Cancer Institute, NIH (Bethesda, MD). Mice with dis-
upted genes in the interferon-a/b receptor (IFNAR1) (Mul-
er et al., 1994) were obtained originally from B&K Universal
td. (Aldbrough, UK) and bred at the Department of Molec-
lar Microbiology and Immunology, The Johns Hopkins Uni-
ersity School of Hygiene and Public Health (Baltimore,
D). Age-matched 129Sv/Ev mice used as controls for the
FNAR1 mice were obtained from Taconic Laboratories
Germantown, NY). At USUHS, all animals were maintained
n standard laboratory feed and water ad libitum in AAA-
AC-accredited animal facilities.
irus, cells, and antibody
Two molecularly cloned VEE strains, virulent V3000
nd attenuated V3032, were used in all the experiments.
he parental V3000 and the single-site-attenuated mu-
ant V3032 differ in their genotype by one single nucle-
tide, resulting in a single amino acid change at E2
lycoprotein position 209, which replaces a glutamic
cid in V3000 with a lysine in V3032 (Grieder et al., 1995).
irus stocks were stored in a Biosafety Level 3 labora-
ory at 280°C.
Primary peritoneal macrophages from C57BL/6 or IRF
nockout mice were generated as previously described
Grieder and Nguyen, 1996). Macrophages were main-
ained in RPMI 1640 medium containing less than 0.005
/ml endotoxin, supplemented with 2% fetal bovine se-
um, 30 mM HEPES buffer, 36 mM NaHCO3, 2 mM L-
lutamine, and antibiotics (100 U/ml penicillin, 100 mg/ml
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117IFN AND IRFs IN EARLY PROTECTION AGAINST VEEtreptomycin). Baby Hamster Kidney 21 (BHK) cells were
btained from the ATCC in passage 53 and maintained
ccording to ATCC guidelines. All experiments including
irus stock preparations and titrations were performed
sing BHK cells between passages 55 and 65.
Purified sheep anti-mouse IFN-a/b antibody was pro-
ided by Dr. Ion Gresser (Viral Oncology, Villejuif Cedex,
rance). Anti-IFN-a/b antibody had a neutralizing titer of
06 against 8 units of IFN-a/b and was added to cell
ultures at a 1:10 dilution in regular growth medium.
ontrol cells were treated with normal goat serum at the
ame concentration.
irulence and early protection
Groups of age- and sex-matched mice were inocu-
ated subcutaneously (sc) into their left rear footpad with
0, 1 3 102, or 1 3 103 plaque forming units (PFU) in a
olume of 25 ml. Percentage mortality and average sur-
ival times 6 standard error (AST 6 SE) were calculated
ollowing an observation period of 14 or 15 days. Only
ead animals were included in the AST calculation. Sur-
iving mice were challenged intraperitoneally with 1 3
04 PFU of virulent V3000 to verify that they were truly
nfected initially. Control groups were injected with iden-
ical volumes of diluent (phosphate-buffered saline con-
aining magnesium, calcium, and 0.1% donor calf serum;
BS–DCS) by the same route.
For early protection experiments, groups of adult con-
rol or knockout mice (IFNAR1 or IRF-1/2) were injected
nto their rear left footpads with 103 PFU of attenuated
3032 followed 24 h later by injection of 102 PFU virulent
3000 into their right rear footpad. The AST were calcu-
ated in days 6 SE unless tissues from infected mice
ere harvested for virus titration.
irus replication in vivo and histopathology
Eight-week-old C57BL/6, IRF-22/2, and IRF-21/2 mice
ere inoculated sc in the left rear footpad with 1 3 103
FU of attenuated V3032 only or with attenuated V3032
ollowed 24 h later with 1 3 102 PFU of virulent V3000 in
he right rear footpad. Control mice were injected with
3 102 PFU V3000 in the right rear footpad only. On days
, 7, or 8 postinfection, mice were anesthetized and
xsanguinated. Sera, spleen, and brain tissues were
arvested for viral titration and for histopathological
nalysis. Fresh tissues were homogenized to make a
0% (w/v) tissue suspension in PBS–DCS. The final sus-
ension was clarified by centrifugation and frozen at
80°C, and standard plaque assay on BHK cells was
sed to determine virus titers per gram fresh tissue.
Tissue samples for histopathological analysis were
ixed in 10% buffered formalin for at least 24 h, embedded
n paraffin, sectioned, and stained with hematoxylin and
osin. Negative controls were tissues of control micenoculated with PBS–DCS and processed in parallel. DCoronal brain sections from C57BL/6 and IRF-22/2 mice
nfected with the attenuated V3032 followed 24 h later with
irulent V3000 and sacrificed on day 5 postinfection were
sed to quantitate the numbers of degenerative neurons in
oth mouse strains. Forty randomly selected high-power
ields in the gray matter in hippocampus sections were
sed to count the total number of degenerating cells lo-
ated in vacular spaces. Only cells with the histological
ppearance of neurons were included in the counts. Low-
ower magnification was used to ensure that only areas
ith similar neuron density were used. Mean numbers of
egenerative cells were calculated and standard Student’s
test was performed.
irus growth kinetics
Primary peritoneal macrophage cultures were grown
n six-well tissue culture plates at 1 3 106 cells per well
or 24 h as described above. Cell cultures treated with
nti-IFN or control antibody were infected with either
3000 or V3032 at a multiplicity of infection of 1 PFU/cell
nd samples from the supernatant were collected over
ime. Virus titers in the supernatants were determined by
tandard plaque assay method on BHK cells (Grieder et
l., 1995).
ACKNOWLEDGMENTS
We thank Ion Gresser for sheep anti-IFN-a/b antibody, Nancy Davis and
ob Johnston for the virulent and attenuated VEE clones, Diane Griffin and
ndrew Byrnes for their generous gift of the IFNAR1 mice, and Ranney
cNally for technical support in the breeding of IRF-1/2 knockout mice. We
cknowledge Diane Griffin and Leslie McKinney for helpful suggestions
nd criticisms in the preparation of the manuscript. This work was sup-
orted by USUHS Grant RO73-DA (F.G.), the Henry Jackson Foundation
rant 0991-731-6619 (F.G.), and PHS-NIH Grant AI-18797 (S.V.).
REFERENCES
alter, M. (1996). HIV’s other immune-system targets: Macrophages
[news]. Science 274, 1464–1465.
en-Nathan, D., Maestroni, G. J., Lustig, S., and Conti, A. (1995). Pro-
tective effects of melatonin in mice infected with encephalitis vi-
ruses. Arch. Virol. 140, 223–230.
ose, H. R., and Sagik, B. P. (1970). The virus envelope in cell attach-
ment. J. Gen. Virol. 9, 159–161.
owen, G. S. (1976). Experimental infection of North American mam-
mals with epidemic Venezuelan encephalitis virus. Am. J. Trop. Med.
Hyg. 25, 891–899.
harles, P. C., Brown, K. W., Davis, N. L., Hart, M. K., and Johnston, R. E.
(1997). Mucosal immunity induced by parenteral immunization with a
live attenuated Venezuelan equine encephalitis virus vaccine candi-
date. Virology 228, 153–160.
hebloune, Y., Karr, B. M., Raghavan, R., Singh, D. K., Leung, K., Sheffer, D.,
Pinson, D., Foresman, L., and Narayan, O. (1998). Neuroinvasion by ovine
lentivirus in infected sheep mediated by inflammatory cells associated
with experimental allergic encephalomyelitis. J. Neurovirol. 4, 38–48.
oppenhaver, D. H., Singh, I. P., Sarzotti, M., Levy, H. B., and Baron, S.
(1995). Treatment of intracranial alphavirus infections in mice by a
combination of specific antibodies and an interferon inducer. Am. J.
Trop. Med. Hyg. 52, 34–40.avis, N. L., Brown, K. W., Greenwald, G. F., Zajac, A. J., Zacny, V. L.,
DD
F
F
F
G
G
G
G
H
H
H
H
J
K
K
L
M
M
M
M
N
P
P
R
R
S
S
T
T
V
W
118 GRIEDER AND VOGELSmith, J. F., and Johnston, R. E. (1995). Attenuated mutants of Vene-
zuelan equine encephalitis virus containing lethal mutations in the
PE2 cleavage signal combined with a second-site suppressor mu-
tation in E1. Virology 212, 102–110.
avis, N. L., Fuller, F. J., Dougherty, W. G., Olmsted, R. A., and Johnston,
R. E. (1986). A single nucleotide change in the E2 glycoprotein gene
of Sindbis virus affects penetration rate in cell culture and virulence
in neonatal mice. Proc. Natl. Acad. Sci. USA 83, 6771–6775.
avis, N. L., Powell, N., Greenwald, G. F., Willis, L. V., Johnson, B. J.,
Smith, J. F., and Johnston, R. E. (1991). Attenuating mutations in the E2
glycoprotein gene of Venezuelan equine encephalitis virus: Con-
struction of single and multiple mutants in a full-length cDNA clone.
Virology 183, 20–31.
ujimura, M., Tominaga, T., Kato, I., Takasawa, S., Kawase, M., Taniguchi,
T., Okamoto, H., and Yoshimoto, T. (1997). Attenuation of nitric oxide
synthase induction in IRF-1-deficient glial cells. Brain Res. 759, 247–250.
ujita, T., Reis, L. F., Watanabe, N., Kimura, Y., Taniguchi, T., and Vilcek,
J. (1989). Induction of the transcription factor IRF-1 and interferon-
beta mRNAs by cytokines and activators of second-messenger path-
ways. Proc. Natl. Acad. Sci. USA 86, 9936–9940.
ujita, T., Sakakibara, J., Sudo, Y., Miyamoto, M., Kimura, Y., and Tan-
iguchi, T. (1988). Evidence for a nuclear factor(s), IRF-1, mediating
induction and silencing properties to human IFN-beta gene regula-
tory elements. EMBO J. 7, 3397–3405.
reenway, T. E., Eldridge, J. H., Ludwig, G., Staas, J. K., Smith, J. F.,
Gilley, R. M., and Michalek, S. M. (1995). Enhancement of protective
immune responses to Venezuelan equine encephalitis (VEE) virus
with microencapsulated vaccine. Vaccine 13, 1411–1420.
rieder, F. B., Davis, B. K., Zhou, X. D., Chen, S. J., Finkelman, F. D., and
Gause, W. C. (1997). Kinetics of cytokine expression and regulation of
host protection following infection with molecularly cloned Venezu-
elan equine encephalitis virus. Virology 233, 302–312.
rieder, F. B., Davis, N. L., Aronson, J. F., Sellon, D. C., Suzuki, K.,
Charles, P. C., and Johnston, R. E. (1995). Specific restrictions in the
progression of Venezuelan equine encephalitis virus induced dis-
ease resulting from single amino acid changes in the glycoprotein.
Virology 206, 994–1006.
rieder, F. B., and Nguyen, H. T. (1996). Virulent and attenuated mutant
Venezuelan equine encephalitis virus show marked differences in rep-
lication in infection in murine macrophages. Microb. Pathog. 21, 85–95.
arada, H., Fujita, T., Miyamoto, M., Kimura, Y., Maruyama, M., Furia, A.,
Miyata, T., and Taniguchi, T. (1989). Structurally similar but function-
ally distinct factors, IRF-1 and IRF-2, bind to the same regulatory
elements of IFN and IFN-inducible genes. Cell 58, 729–739.
art, M. K., Pratt, W., Panelo, F., Tammariello, R., and Dertzbaugh, M.
(1997). Venezuelan equine encephalitis virus vaccines induce muco-
sal IgA responses and protection from airborne infection in BALB/c,
but not C3H/HeN mice. Vaccine 15, 363–369.
uprikar, J., Dal Canto, M. C., and Rabinowitz, S. G. (1990). Protection
against lethal Venezuelan equine encephalitis (VEE) virus infection
by cell-free supernatant obtained from immune spleen cells. J. Neu-
rol. Sci. 97, 143–153.
wang, S. Y., Hertzog, P. J., Holland, K. A., Sumarsono, S. H., Tymms,
M. J., Hamilton, J. A., Whitty, G., Bertoncello, I., and Kola, I. (1995). A
null mutation in the gene encoding a type I interferon receptor
component eliminates antiproliferative and antiviral responses to
interferons alpha and beta and alters macrophage responses. Proc.
Natl. Acad. Sci. USA 92, 11284–11288.
ackson, A., Sen Gupta, S., and Smith, J. (1991). Pathogenesis of Ven-
ezuelan equine encephalitis virus infection in mice and hamsters.
Vet. Pathol. 28, 410–418.
amijo, R., Harada, H., Matsuyama, T., Bosland, M., Gerecitano, J.,
Shapiro, D., Le, J., Koh, S. I., Kimura, T., Green, S. J., et al. (1994).
Requirement for transcription factor IRF-1 in NO synthase induction
in macrophages. Science 263, 1612–1615.imura, T., Nakayama, K., Penninger, J., Kitagawa, M., Harada, H.,
Matsuyama, T., Tanaka, N., Kamijo, R., Vilcek, J., Mak, T. W., et al.
(1994). Involvement of the IRF-1 transcription factor in antiviral re-
sponses to interferons. Science 264, 1921–1924.
ehtonen, A., Matikainen, S., and Jukunen, I. (1997). Interferons up-
regulate STAT1, STAT2, and IRF family transcription factor gene ex-
pression in human peripheral blood mononuclear cells and macro-
phages. J. Immunol. 159, 794–803.
acDonald, G. H., Davis, N. L., and Johnston, R. E. (1997). Venezuelan equine
encephalitis virus targets dendritic cells in the draining lymph node. In
“Abstracts, American Society for Virology, 16th Annual Meeting,” p. 172.
atsuyama, T., Kimura, T., Kitagawa, M., Pfeffer, K., Kawakami, T.,
Watanabe, N., Kundig, T. M., Amakawa, R., Kishihara, K., Wakeham,
A., et al. (1993). Targeted disruption of IRF-1 or IRF-2 results in
abnormal type I IFN gene induction and aberrant lymphocyte devel-
opment. Cell 75, 83–97.
iyamoto, M., Fujita, T., Kimura, Y., Maruyama, M., Harada, H., Sudo, Y.,
Miyata, T., and Taniguchi, T. (1988). Regulated expression of a gene
encoding a nuclear factor, IRF-1, that specifically binds to IFN-beta
gene regulatory elements. Cell 54, 903–913.
uller, U., Steinhoff, U., Reis, L. F., Hemmi, S., Pavlovic, J., Zinkernagel,
R. M., and Aguet, M. (1994). Functional role of type I and type II
interferons in antiviral defense. Science 264, 1918–1921.
guyen, H., Lin, R., and Hiscott, J. (1997). Activation of multiple growth
regulatory genes following inducible expression of IRF-1 or IRF/RelA
fusion proteins. Oncogene 15, 1425–1435.
itha, P. M. (1997). Reflections on the years in interferon research.
J. Interferon Cytokine Res. 17, 181–184.
ittman, P. R., Makuch, R. S., Mangiafico, J. A., Cannon, T. L., Gibbs,
P. H., and Peters, C. J. (1996). Long-term duration of detectable
neutralizing antibodies after administration of live-attenuated VEE
vaccine and following booster vaccination with inactivated VEE vac-
cine. Vaccine 14, 337–343.
ivas, F., Diaz, L. A., Cardenas, V. M., Daza, E., Bruzon, L., Alcala, A., De
la Hoz, O., Caceres, F. M., Aristizabal, G., Martinez, J. W., Revelo, D.,
De la Hoz, F., Boshell, J., Camacho, T., Calderon, L., Olano, V. A.,
Villarreal, L. I., Roselli, D., Alvarez, G., Ludwig, G., and Tsai, T. (1997).
Epidemic Venezuelan equine encephalitis in La Guajira, Colombia,
1995. J. Infect. Dis. 175, 828–832.
ossi, C. P., Delcroix, M., Huitinga, I., McAllister, A., van Rooijen, N.,
Claassen, E., and Brahic, M. (1997). Role of macrophages during
Theiler’s virus infection. J. Virol. 71, 3336–3340.
alkowski, C. A., Barber, S. A., Detore, G. R., and Vogel, S. N. (1996).
Differential dysregulation of nitric oxide production in macrophages
with targeted disruptions in IFN regulatory factor-1 and -2 genes.
J. Immunol. 156, 3107–3110.
trauss, J. H., and Strauss, E. G. (1994). The alphaviruses: Gene ex-
pression, replication, and evolution. Microbiol. Rev. 58, 491–562.
[Published erratum appears in Microbiol. Rev., 1994, 58, 806]
rgovcich, J., Aronson, J. F., and Johnston, R. E. (1996). Fatal Sindbis
virus infection of neonatal mice in the absence of encephalitis.
Virology 224, 73–83.
rgovcich, J., Ryman, K., Extrom, P., Eldridge, J. C., Aronson, J. F., and
Johnston, R. E. (1997). Sindbis virus infection of neonatal mice results
in a severe stress response. Virology 227, 234–238.
ictor, J. S., D. G., and Pollack, A. D. (1956). The comparative pathology
of Venezuelan equine encephalitis. J. Infect. Dis. 98, 55–66.
atts, D. M., Lavera, V., Callahan, J., Rossi, C., Oberste, M. S., Roehrig, J. T.,
Cropp, C. B., Karabatsos, N., Smith, J. F., Gubler, D. J., Wooster, M. T.,
Nelson, W. M., and Hayes, C. G. (1997). Venezuelan equine encephalitis
and Oropouche virus infections among Peruvian army troops in the
Amazon region of Peru. Am. J. Trop. Med. Hyg. 56, 661–667.
